UCB SA ADR (UCBJY)

Currency in USD
150.19
-0.67(-0.44%)
Closed·
Unusual trading volume
UCBJY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
148.78151.40
52 wk Range
71.15151.76
Key Statistics
Prev. Close
150.86
Open
151.4
Day's Range
148.78-151.4
52 wk Range
71.15-151.76
Volume
77.86K
Average Volume (3m)
27.48K
1-Year Change
52.423%
Book Value / Share
60.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
UCBJY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
162.02
Upside
+7.87%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 16 consecutive years

UCB SA ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

UCB SA ADR Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Employees
8600

Compare UCBJY to Peers and Sector

Metrics to compare
UCBJY
Peers
Sector
Relationship
P/E Ratio
37.1x24.4x−0.6x
PEG Ratio
0.080.000.00
Price/Book
5.1x5.1x2.6x
Price / LTM Sales
7.2x3.4x3.4x
Upside (Analyst Target)
7.7%17.1%41.3%
Fair Value Upside
Unlock13.2%4.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 162.02
(+7.87% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.87%
Dividend Yield
0.32%
Industry Median 2.52%
Annualized payout
0.48
Paid unevenly
5-Years Growth
+2.31%
Growth Streak

Earnings

Latest Release
Nov 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / 2.37B
EPS Revisions
Last 90 days

UCBJY Income Statement

People Also Watch

1.830
EUDA
-4.19%
26.91
BMRC
+2.13%
318.78
BAP
+0.56%
813.24
ARGX
+1.74%
14.22
ALPMY
-1.93%

FAQ

What Is the UCB ADR (UCBJY) Stock Price Today?

The UCB ADR stock price today is 150.19

What Stock Exchange Does UCB ADR Trade On?

UCB ADR is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for UCB ADR?

The stock symbol for UCB ADR is "UCBJY."

Does UCB ADR Pay Dividends? What’s The Current Dividend Yield?

The UCB ADR dividend yield is 0.32%.

What Is the UCB ADR Market Cap?

As of today, UCB ADR market cap is 57.22B.

What Is UCB ADR's Earnings Per Share (TTM)?

The UCB ADR EPS (TTM) is 6.87.

When Is the Next UCB ADR Earnings Date?

UCB ADR will release its next earnings report on Feb 26, 2026.

From a Technical Analysis Perspective, Is UCBJY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has UCB ADR Stock Split?

UCB ADR has split 0 times.

How Many Employees Does UCB ADR Have?

UCB ADR has 8600 employees.

What is the current trading status of UCB ADR (UCBJY)?

As of Jan 16, 2026, UCB ADR (UCBJY) is trading at a price of 150.19, with a previous close of 150.86. The stock has fluctuated within a day range of 148.78 to 151.40, while its 52-week range spans from 71.15 to 151.76.

What Is UCB ADR (UCBJY) Price Target According to Analysts?

The average 12-month price target for UCB ADR is USD162.01683111, with a high estimate of USD163.16192687 and a low estimate of USD160.87173535. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7.87% Upside potential.

What Is the UCBJY After Hours Price?

UCBJY's last after hours stock price is 151.49, the stock has decreased by 0.63, or 0.42%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.